![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
1. Ly317615.hcl
1. 170364-57-5
2. Ly317615
3. Enzastaurin (ly317615)
4. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione
5. Ly-317615
6. 3-(1-methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione
7. Db102
8. Uc96g28eqf
9. Ly 317615
10. Chembl300138
11. Db-102
12. Dsstox_cid_24029
13. Dsstox_rid_80101
14. Dsstox_gsid_44029
15. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)-piperidin-4-yl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione
16. 1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-
17. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-1h-pyrrole-2,5-dione
18. 3-(1-methyl-1h-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl}-1h-pyrrole-2,5-dione
19. Enzastaurin [inn]
20. Cas-170364-57-5
21. Unii-uc96g28eqf
22. 3-(1-methyl-1h-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione
23. Le-0014
24. Enzastaurin [mi]
25. Enzastaurin [usan:inn]
26. Enzastaurin,ly317615
27. Enzastaurin [usan]
28. Enzastaurin; Ly317615
29. Enzastaurin [who-dd]
30. Ly317615 - Enzastaurin
31. Schembl678748
32. Gtpl5693
33. Dtxsid5044029
34. Chebi:91368
35. Amy7827
36. Bcpp000241
37. Hms3265m05
38. Hms3265m06
39. Hms3265n05
40. Hms3265n06
41. Hms3654a13
42. Hms3748e03
43. Bcp02703
44. Ex-a1055
45. Who 8426
46. Zinc1494900
47. Tox21_113367
48. Bdbm50128285
49. Mfcd11040980
50. Nsc767124
51. Nsc800096
52. S1055
53. Akos015994764
54. Tox21_113367_1
55. Ac-5900
56. Bcp9000648
57. Ccg-264797
58. Cs-0132
59. Db06486
60. Nsc-767124
61. Nsc-800096
62. Sb16481
63. Ncgc00238452-01
64. Ncgc00238452-02
65. Ncgc00238452-03
66. Ncgc00238452-11
67. Hy-10342
68. Db-064781
69. Ft-0667873
70. Sw219797-1
71. Ec-000.2315
72. 364e575
73. J-510442
74. Q5381479
75. Brd-k79404599-001-01-0
76. 3-(1-methyl-1h-indol-3-yl)-4-(1-(1-(2-pyridinylmethyl)-4-piperidinyl)-1h-indol-3-yl)-1h-pyrrole-2,5-
77. 3-(1-methyl-1h-indol-3-yl)-4-[1-(1-pyridin-2-ylmethyl-piperidin-4-yl)-1h-indol-3-yl]-pyrrole-2,5-dione
78. 3-(1-methyl-1h-indol-3-yl)-4-{1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl}-2,5-dihydro-1h-pyrrole-2,5-dione
Molecular Weight | 515.6 g/mol |
---|---|
Molecular Formula | C32H29N5O2 |
XLogP3 | 3.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 5 |
Exact Mass | 515.23212518 g/mol |
Monoisotopic Mass | 515.23212518 g/mol |
Topological Polar Surface Area | 72.2 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 974 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.
Enzastaurin is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through multiple mechanisms. Preclinical data indicate it may reduce the cell's ability to reproduce (cell proliferation), increase the natural death of the tumor cells (apoptosis), and inhibit tumor- induced blood supply (angiogenesis). Enzastaurin has been shown to inhibit signaling through the PKC-B and PI3K/AKT pathways. These pathways have been shown to be activated in a wide variety of cancers. In addition to glioblastoma, enzastaurin is also being studied in multiple other tumor types, including non-Hodgkin's lymphoma, colorectal cancer, non-small cell lung cancer, pancreatic cancer, and mantle cell lymphoma.